TauRx Reports First Phase 3 Results for LMTX® - Seite 3

Data Presentation Details 

Study TRx-237-015 will be presented at an oral session at AAIC on 27 July 2016, 16:15-17:45.

Tau aggregation inhibitors 

TauRx's tau aggregation inhibitors (TAIs) have arisen from nearly 30 years of research. TAIs work by undoing the tau tangles that cause dementia, thereby slowing and even arresting memory loss^[1]. The first-generation TAI, rember^®, was a patented, highly-purified version of methylene blue, a compound previously used to treat a variety of conditions.

About TauRx Therapeutics Ltd 

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group which is developing technology spun-out from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's tau aggregation inhibitor, LMTX^® targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to 'tau tangles'. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen. For more information, please visit: http://www.taurx.com.

References 

1. Wischik CM, et al. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 2014;88:529-39.

Email: [e-mail]

Website: http://www.taurx.com